Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 6887 · · 10 pages · English
Earlier from Sunshine Lake Pharma Co., Ltd. Class H
- Interim Report 2026
- Next Day Disclosure Return
- Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA™ an Interchangeable Biosimilar of Lantus® (insulin glargine)
- Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion